top of page
Backgrounds.jpg

The voice of Colville and northeastern Washington since 1896

|

September 15, 2026

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evofem Biosciences, Inc. - Common Stock (OP:EVFM)

0.0080 +0.0005 (+6.67%)
Streaming Delayed Price Updated: 2:29 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 94,843
Open 0.0081
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0075
Today's Range 0.0077 - 0.0081
52wk Range 0.0008 - 0.0200
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
HUB Cyber Security Expands Into Women’s Health With Zero-Cash Acquisition of Evofem Notes, Advances Balance Sheet Turnaround
Move Expands HUB’s Footprint Into Women’s Health and Wellness, a Sector With Significant Commercial Revenue Potential, as Company Advances Broader Turnaround Strategy 
From HUB Cyber Security Ltd
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MLNK, BFIN, MRCC, EVFM on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire

Performance

YTD
-15.8%
-15.8%
1 Month
-3.6%
-3.6%
3 Month
N/A
N/A
6 Month
-9.1%
-9.1%
1 Year
-42.4%
-42.4%

More News

Read More
News headline image
Evofem Revenue Jumps 16 Percent in Q2 ↗
Via The Motley Fool
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
Via Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
Via Investor Brand Network
News headline image
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
From Aditxt, Inc.
Via Business Wire
News headline image
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Gains Support for Evofem Merger as Voting Agreements Secure Favorable Votes
Via Investor Brand Network
News headline image
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
From Aditxt, Inc.
Via Business Wire
News headline image
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
From Aditxt, Inc.
Via Business Wire
News headline image
Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves Closer to Evofem Acquisition with Final Investment Milestone
Via Investor Brand Network
News headline image
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
From Aditxt, Inc.
Via Business Wire
News headline image
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX), Evofem Announce Completion of Third Parent Equity Investment Under Amended Merger Agreement
Via Investor Brand Network
InvestorNewsBreaks – Gaxos.ai Inc. (NASDAQ: GXAI) Announces Participation at the Upcoming Game Industry Conference
Via Investor Brand Network
News headline image
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Releases Shareholder Update, Plans for Remainder of 2024
Via Investor Brand Network
News headline image
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Acquisition Target Files Preliminary Proxy Seeking Stockholder Approval
Via Investor Brand Network
News headline image
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Subsidiary Signs Agreement with Evofem Biosciences Inc. (OTCQB: EVFM) Involving Unique Endometriosis Diagnostic Test
Via Investor Brand Network
News headline image
Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
From Aditxt, Inc.
Via Business Wire
News headline image
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
From Aditxt, Inc.
Via Business Wire
News headline image
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
From Aditxt, Inc.
Via Business Wire

Frequently Asked Questions

Is Evofem Biosciences, Inc. - Common Stock publicly traded?
Yes, Evofem Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Evofem Biosciences, Inc. - Common Stock trade on?
Evofem Biosciences, Inc. - Common Stock trades on the OTC Traded
What is the ticker symbol for Evofem Biosciences, Inc. - Common Stock?
The ticker symbol for Evofem Biosciences, Inc. - Common Stock is EVFM on the OTC Traded
What is the current price of Evofem Biosciences, Inc. - Common Stock?
The current price of Evofem Biosciences, Inc. - Common Stock is 0.0080
When was Evofem Biosciences, Inc. - Common Stock last traded?
The last trade of Evofem Biosciences, Inc. - Common Stock was at 09/30/26 02:29 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page